Health Catalyst (HCAT) Set to Post Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $55.39 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $70.49 million during the quarter, compared to analysts’ expectations of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. On average, analysts expect Health Catalyst to post ($0.18) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

Health Catalyst Trading Down 4.7%

NASDAQ HCAT traded down $0.07 on Tuesday, hitting $1.50. 218,523 shares of the company were exchanged, compared to its average volume of 937,007. The company’s 50 day moving average price is $1.72 and its 200-day moving average price is $1.72. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.70 and a quick ratio of 2.70. The firm has a market capitalization of $113.27 million, a P/E ratio of -0.41 and a beta of 1.54. Health Catalyst has a twelve month low of $0.96 and a twelve month high of $3.36.

Insider Buying and Selling

In related news, CEO Simeon Kohl bought 59,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were bought at an average cost of $1.79 per share, for a total transaction of $105,610.00. Following the completion of the acquisition, the chief executive officer directly owned 2,856,385 shares in the company, valued at approximately $5,112,929.15. This represents a 2.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 19.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HCAT. Weiss Ratings restated a “sell (d-)” rating on shares of Health Catalyst in a research note on Monday, October 26th. Wells Fargo & Company cut their price target on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research note on Thursday, August 13th. Canaccord Genuity Group downgraded Health Catalyst from a “buy” rating to a “hold” rating and cut their price target for the stock from $3.00 to $1.80 in a research note on Thursday, August 20th. Finally, Citigroup reduced their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.01.

About Health Catalyst

Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.

The company’s offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.